A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), Ronnie Shapira‐Frommer(Sheba Medical Center), Samuel McNeely(Eli Lilly (United States)), Ignace Vergote(KU Leuven), Rowan Miller(Queen Mary University of London), Bo Gao(Sun Yat-sen University), Jung‐Yun Lee(Yonsei University), Jungmin Lee(National Cancer Institute), Nicoletta Colombo(University of Milano-Bicocca), Suzanne R.L. Young(Eli Lilly (United States)), Xuejing Aimee Wang(Eli Lilly (United States)), Aimee Bence Lin(Eli Lilly (United States)), Kelly M. Credille(Eli Lilly (United States))
Cited by 66
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k